by
Lisa Chamoff, Contributing Reporter | October 29, 2018
From the October 2018 issue of HealthCare Business News magazine
Dempsey notes that the clinical data shows that the MRIdian can treat cancer with lower toxicity.
“The biggest headlines for us are the clinical data,” Dempsey said.
Ad Statistics
Times Displayed: 46636
Times Visited: 1410 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Xstrahl
In December 2017, Xstrahl launched the new RADiant X-ray radiation therapy system with an FDA 510(k) clearance, which was followed by a CE mark in March 2018.
The RADiant system offers two types of treatment – electronic brachytherapy (eBX) and superficial radiotherapy (SRT), which is different from conventional radiotherapy systems currently on the market, according to Adrian Treverton, chief operating officer of Xstrahl Inc. This allows customers to increase their throughput and allows for adoption by the American dermatological market, which cannot use the high-powered radiotherapy systems currently on the market.
“The radiotherapy industry current has two main trends – a significant increase in skin cancers and skin conditions worldwide, and increased pressures on departments and clinics to treat patients in cost- and time-effective ways,” said Treverton. “The RADiant offers a cost-effective treatment platform treating not only skin cancers, but also non-malignant skin conditions, keloids and dermatological conditions, allowing for reduced pressure on oncology departments, and an increase of client base for dermatological clinics.”
RADiant is currently installed at four sites across the continental U.S., both in radiotherapy oncology departments and dermatology clinics. The RADiant will also soon be released in Europe, South America and China, before a full worldwide rollout.
Back to HCB News
